247 related articles for article (PubMed ID: 28322941)
1. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
Kashihara Y; Ieiri I; Yoshikado T; Maeda K; Fukae M; Kimura M; Hirota T; Matsuki S; Irie S; Izumi N; Kusuhara H; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2688-2694. PubMed ID: 28322941
[TBL] [Abstract][Full Text] [Related]
2. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
Ieiri I; Doi Y; Maeda K; Sasaki T; Kimura M; Hirota T; Chiyoda T; Miyagawa M; Irie S; Iwasaki K; Sugiyama Y
J Clin Pharmacol; 2012 Jul; 52(7):1078-89. PubMed ID: 21593283
[TBL] [Abstract][Full Text] [Related]
3. Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1.
Medwid S; Li MMJ; Knauer MJ; Lin K; Mansell SE; Schmerk CL; Zhu C; Griffin KE; Yousif MD; Dresser GK; Schwarz UI; Kim RB; Tirona RG
Drug Metab Dispos; 2019 Aug; 47(8):832-842. PubMed ID: 31123035
[TBL] [Abstract][Full Text] [Related]
4. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
Safar Z; Kis E; Erdo F; Zolnerciks JK; Krajcsi P
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):313-328. PubMed ID: 30856014
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
Kim TE; Shin D; Gu N; Jung BH; Kim J; Cho YM; Yu KS; Cho JY
Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):195-201. PubMed ID: 28627804
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting inhibitory effect of apple and orange juices, but not grapefruit juice, on OATP2B1-mediated drug absorption.
Shirasaka Y; Shichiri M; Murata Y; Mori T; Nakanishi T; Tamai I
Drug Metab Dispos; 2013 Mar; 41(3):615-21. PubMed ID: 23264447
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
8. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions.
Shirasaka Y; Shichiri M; Mori T; Nakanishi T; Tamai I
J Pharm Sci; 2013 Sep; 102(9):3418-26. PubMed ID: 23794501
[TBL] [Abstract][Full Text] [Related]
9. Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.
Shirasaka Y; Mori T; Murata Y; Nakanishi T; Tamai I
Pharm Res; 2014 Aug; 31(8):2035-43. PubMed ID: 24549825
[TBL] [Abstract][Full Text] [Related]
10. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
Sasabe H; Shimokawa Y; Shibata M; Hashizume K; Hamasako Y; Ohzone Y; Kashiyama E; Umehara K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3497-508. PubMed ID: 27021329
[TBL] [Abstract][Full Text] [Related]
11. The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion.
Akamine Y; Miura M; Komori H; Tamai I; Ieiri I; Yasui-Furukori N; Uno T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):352-7. PubMed ID: 26213156
[TBL] [Abstract][Full Text] [Related]
12. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
Karibe T; Hagihara-Nakagomi R; Abe K; Imaoka T; Mikkaichi T; Yasuda S; Hirouchi M; Watanabe N; Okudaira N; Izumi T
Pharm Res; 2015 May; 32(5):1634-47. PubMed ID: 25380981
[TBL] [Abstract][Full Text] [Related]
14. Comparison of inhibitory duration of grapefruit juice on organic anion-transporting polypeptide and cytochrome P450 3A4.
Tanaka S; Uchida S; Miyakawa S; Inui N; Takeuchi K; Watanabe H; Namiki N
Biol Pharm Bull; 2013; 36(12):1936-41. PubMed ID: 24292052
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
J Pharm Sci; 2015 Sep; 104(9):3039-48. PubMed ID: 25639366
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
18. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta.
Grube M; Reuther S; Meyer Zu Schwabedissen H; Köck K; Draber K; Ritter CA; Fusch C; Jedlitschky G; Kroemer HK
Drug Metab Dispos; 2007 Jan; 35(1):30-5. PubMed ID: 17020956
[TBL] [Abstract][Full Text] [Related]
19. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
Hua WJ; Hua WX; Fang HJ
Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
